Beyond Air reports Q2 EPS (51c), consensus (47c)

Reports Q2 revenue $239,000, consensus $480,000. “The Beyond Air and Beyond Cancer teams continue to execute. In the last three months, we have made significant strides in the US hospital market with LungFit PH, licensed LungFit PH in certain Asian markets, submitted a PMA supplement to the FDA for cardiac surgery, presented preclinical and human data for treatment of solid tumors with UNO and began the United States VCAP study,” said Steve Lisi, Chairman and Chief Executive Officer of Beyond Air. “Market confidence in our superior LungFit PH technology continues to grow along with our market penetration and opportunities. I am proud of our progress and want to thank our customers who gave us the opportunity to succeed over the past year. At the American Academy of Respiratory Care (AARC) last week there was great enthusiasm around our enhanced LungFit PH system which gives us confidence in our fiscal 2025 revenue guidance as well as our belief that LungFit PH will become the dominant product in the market”.